产品
编 号：F761002
分子式：C25H35N5O2
分子量：437.58
分子式：C25H35N5O2
分子量：437.58
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 873546-31-7
产品详情
生物活性：
T-2307, an arylamidine, has antifungal activities in vitro and in vivo. T-2307 exhibits broad-spectrum activity against clinically significant pathogens, including?Candida?species (MIC range, 0.00025 to 0.0078 μg/ml),?Cryptococcus neoformans?(MIC range, 0.0039 to 0.0625 μg/ml), and?Aspergillus?species (MIC range, 0.0156 to 4 μg/mL) .
体内研究：
In mouse models of disseminated candidiasis, cryptococcosis, and aspergillosis, the ED50 of T-2307 were 0.00755, 0.117, and 0.391 mg/kg, respectively.Animal Model:4-week-old specific-pathogen-free ICR strain male mice bearing systemic infections with?Candida albicans, Cryptococcus neoformans, and?Aspergillus fumigatus.
Dosage:0.001, 0.1, 1 mg/kg
Administration:Subcutaneously administered; once a day for 7 days, beginning at 2 h after the infection.
Result:In the systemic infection caused by?Candida albicans, all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 0.01 mg/kg?compared with that in the control mice. The calculated ED50s of T-2307were 0.00755 mg/kg. In the systemic infection caused by?Cryptococcus neoformans, all the control mice died by day 9. Mortality was significantly delayed in mice administered T-2307 at a dose of 0.1 mg/kg?compared with that in the control mice. The calculated ED50s of T-2307 were 0.117 mg/kg. In the systemic infection caused by?Aspergillus fumigatus, all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 1 mg/kg compared with that in the control mice. The calculated ED50s of T-2307 were 0.391 mg/kg.
体外研究：
T-2307 exhibits potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent?Candida albicans?strains as well as against azole-susceptible strains. T-2307 shows efficacy in a murine model of?candida glabrata?infection despite?in vitro?trailing growth phenomena.
T-2307, an arylamidine, has antifungal activities in vitro and in vivo. T-2307 exhibits broad-spectrum activity against clinically significant pathogens, including?Candida?species (MIC range, 0.00025 to 0.0078 μg/ml),?Cryptococcus neoformans?(MIC range, 0.0039 to 0.0625 μg/ml), and?Aspergillus?species (MIC range, 0.0156 to 4 μg/mL) .
体内研究：
In mouse models of disseminated candidiasis, cryptococcosis, and aspergillosis, the ED50 of T-2307 were 0.00755, 0.117, and 0.391 mg/kg, respectively.Animal Model:4-week-old specific-pathogen-free ICR strain male mice bearing systemic infections with?Candida albicans, Cryptococcus neoformans, and?Aspergillus fumigatus.
Dosage:0.001, 0.1, 1 mg/kg
Administration:Subcutaneously administered; once a day for 7 days, beginning at 2 h after the infection.
Result:In the systemic infection caused by?Candida albicans, all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 0.01 mg/kg?compared with that in the control mice. The calculated ED50s of T-2307were 0.00755 mg/kg. In the systemic infection caused by?Cryptococcus neoformans, all the control mice died by day 9. Mortality was significantly delayed in mice administered T-2307 at a dose of 0.1 mg/kg?compared with that in the control mice. The calculated ED50s of T-2307 were 0.117 mg/kg. In the systemic infection caused by?Aspergillus fumigatus, all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 1 mg/kg compared with that in the control mice. The calculated ED50s of T-2307 were 0.391 mg/kg.
体外研究：
T-2307 exhibits potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent?Candida albicans?strains as well as against azole-susceptible strains. T-2307 shows efficacy in a murine model of?candida glabrata?infection despite?in vitro?trailing growth phenomena.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备